Venclaxta/Venclaxto (Venetoclax) monotherapy has shown high response rates and well tolerated safety profile in patients with relapsed or refractory chronic lymphocytic Leukaemia (CLL). Some early data from phase I study has also highlighted its potential in treatment of acute myeloid leukaemia and multiple myeloma. This new data from multiple studies were presented by Roche at […]

The post BCL-2 Inhibitors: Venclaxta showed promising results in leukaemia with 17p deletion appeared first on Innoplexus.